Wintac Limited is an India-based company, which is engaged in the formulations business. The Company is involved in formulation sales, manufacturing charges and formulation development. Its products are classified under categories, including injectable and ophthalmic. Its ophthalmic product range includes Timolol Maleate Eye Drops, Atropine Eye Drops, Fluorometholone Eye Drops, Olopatadine Eye Drops, Chloramphenicol Eye Drops, Diclofenac Eye Drops, Ketorolac Tromethamine Eye Drops and Bromfenac Eye Drops. Its injectable product range includes Diclofenac Injection, Pheniramine Maleate Injection, Iron Sucrose Injection, Pentoxifylline Injection, Atropine Injection, Hyoscine Butyl Bromide Injection, Ondansetron Injection, Metoclopramide Injection, Tramadol Injection, Analgin Injection, Gentamicin Sulphate Injection and Levofloxacin Injection. The Company carries out formulation development activities in the export market, including the United States, Canada, Australia and Europe.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.